Sol-Gel Technologies (SLGL) Change in Receivables (2019 - 2023)
Sol-Gel Technologies (SLGL) reported Change in Receivables of $2.2 million for Q2 2023, down 78.33% year-over-year from $10.2 million in Q2 2022, and down 62.02% quarter-over-quarter from $5.8 million in Q1 2023.
Sol-Gel Technologies (SLGL) Change in Receivables (2019 - 2023) Analysis & Trends
Sol-Gel Technologies (SLGL) has 5 years of Change in Receivables data on file, last reported at $2.2 million in Q2 2023.
- Change in Receivables for Q2 2023 came in at $2.2 million, down 78.33% year-over-year; the trailing twelve-month figure through Jun 2023 was $2.2 million (down 78.33% YoY), and the FY2024 annual result was $3.2 million, up 921.59% from the prior year.
- Change in Receivables eased to $2.2 million in Q2 2023 per SLGL's latest filing, from $5.8 million in the prior quarter.
- Over five years, Change in Receivables peaked at $13.1 million in Q4 2021 and troughed at $706000.0 in Q1 2021.
- A 5-year average of $5.3 million and a median of $4.2 million in 2019 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2020 and 2022: Change in Receivables tumbled 85.04% in 2020, then soared 1268.27% in 2022.
- A 5-year view of Change in Receivables shows it stood at $4.8 million in 2019, then slumped by 55.13% to $2.2 million in 2020, then surged by 506.83% to $13.1 million in 2021, then slumped by 39.85% to $7.9 million in 2022, then plunged by 71.94% to $2.2 million in 2023.
- Business Quant data shows SLGL's Change in Receivables at $2.2 million in Q2 2023, $5.8 million in Q1 2023, and $7.9 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2.21 Mn |
| Jun 30, 2023 | 2.21 Mn |
| Mar 31, 2023 | 5.81 Mn |
| Mar 31, 2023 | 5.81 Mn |
| Dec 31, 2022 | 7.86 Mn |
| Dec 31, 2022 | 7.86 Mn |
| Sep 30, 2022 | 10.78 Mn |
| Sep 30, 2022 | 10.78 Mn |
| Jun 30, 2022 | 10.18 Mn |
| Jun 30, 2022 | 10.18 Mn |
| Mar 31, 2022 | 9.66 Mn |
| Mar 31, 2022 | 9.66 Mn |
| Dec 31, 2021 | 13.07 Mn |
| Dec 31, 2021 | 13.07 Mn |
| Sep 30, 2021 | 1.39 Mn |
| Sep 30, 2021 | 1.39 Mn |
| Jun 30, 2021 | 956,000.00 |
| Jun 30, 2021 | 956,000.00 |
| Mar 31, 2021 | 706,000.00 |
| Mar 31, 2021 | 706,000.00 |